Strata Critical Medical (SRTA) Current Deferred Revenue (2019 - 2025)

Strata Critical Medical (SRTA) has 7 years of Current Deferred Revenue data on file, last reported at $9.1 million in Q2 2025.

• Quarterly Current Deferred Revenue fell 1.66% year-over-year to $9.1 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $9.1 million (down 1.66% YoY) and the FY2024 annual result came in at $6.7 million, down 2.76% from the prior year.
• Current Deferred Revenue improved to $9.1 million in Q2 2025 per SRTA's latest filing, from $8.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $10.0 million in Q2 2023 and bottomed at $4.4 million in Q1 2021.
• The 5-year median for Current Deferred Revenue is $6.8 million (2022), against an average of $7.1 million.
• The widest annual swing landed in 2022, when Current Deferred Revenue jumped 61.41%; it then fell 7.47% in 2024.
• Tracing SRTA's Current Deferred Revenue over 5 years: stood at $6.0 million in 2021, then gained by 12.27% to $6.7 million in 2022, then grew by 2.03% to $6.8 million in 2023, then dropped by 2.76% to $6.7 million in 2024, then soared by 36.9% to $9.1 million in 2025.
• Per Business Quant, the three latest SRTA Current Deferred Revenue figures stand at $9.1 million (Q2 2025), $8.0 million (Q1 2025), and $6.7 million (Q4 2024).

Peer Comparison